Intellipharmaceutics Logo

Email this page: News Release

Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA

 

Separate multiple addresses with commas. Maximum 200 characters.
 
 


These email addresses will be used to email the page on your behalf and will not be used by Intellipharmaceutics for any marketing purposes.

Send:       


 
This helps Intellipharmaceutics prevent automated submissions.